Rapidly Progressive Glomerulonephritis (RPGN) Flashcards

1
Q

rapidly progressive glomerulonephritis (RPGN) - defined

A

*clinical syndrome: acute glomerulonephritis associated with a rapid onset of severe acute kidney injury
*pathologic feature: crescents on light microscopy
*usually caused by processes that cause nephritic syndrome (the “extreme” of nephritic syndrome)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

rapidly progressive glomerulonephritis (RPGN) - clinical features

A

*oliguria
*rapid renal failure
*variable proteinuria
*hematuria
*hypertension, often severe

essentially, severe nephritic syndrome with rapid loss of GFR

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

oliguria - defined

A

low urine output < 400 ml/day

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

rapidly progressive glomerulonephritis (RPGN) - urine findings

A

*RBCs and RBC casts
*dysmorphic RBCs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

rapidly progressive glomerulonephritis (RPGN) - the CRESCENT

A

*crescents consist of fibrin & plasma proteins with glomerular parietal cells, monocytes, macrophages
*crescents are induced in the glomerular capillary wall, resulting in:
-movement of plasma products, including fibrinogen, into Bowman’s space with subsequent fibrin formation
-influx of macrophages and T cells
-release of proinflammatory cytokines (IL-1, TNF-alpha)

*crescent organization: cellular → fibrocellular → fibrous

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

3 main glomerular insults that cause RPGN

A
  1. anti-GBM disease (antibodies directly targeting the GBM)
  2. immune complex diseases (nephritic type immune complex disease, typically with subendothelial immune complexes that can cause severe injury)
  3. Pauci immune glomerulonephritis (anti-neutrophil cytoplasmic antibodies [ANCA] activate circulating immune cells which result in cell-mediated damage)
    -includes GPA, EGPA, and microscopic polyangiitis (MPA)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

anti-glomerular basement membrane disease (anti-GBM) - light microscopy findings

A

*breaks of the GBM due to fibrinoid necrosis
*CRESCENTS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

anti-glomerular basement membrane disease (anti-GBM) - immunofluorescence findings

A

*strong linear GBM staining for IgG
*this is DIAGNOSTIC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

anti-glomerular basement membrane disease (anti-GBM) - electron microscopy findings

A

no deposits

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

anti-glomerular basement membrane disease (anti-GBM) - etiology

A

*development of (usually IgG) autoantibodies against the non-collagenous C-terminal domain of alpha 3 subunit of type IV collagen
*development of disease is sometimes preceded by a flu-like illness (virus) or hydrocarbon or solvent exposure
*also associated with cigarette smoking
*exposure of an antigen/domain of type IV collagen that is not normally seen by the immune system
*anti-GBM disease can occur in Alport Syndrome patients who have received kidney transplant

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

anti-glomerular basement membrane disease (anti-GBM) - epidemiology

A

*renal and pulmonary: men aged 20-40
*renal limited: women aged > 60

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

anti-glomerular basement membrane disease (anti-GBM) - clinical presentation

A

*isolated renal disease or with cross-reaction with alveolar basement membranes, causing pulmonary hemorrhage (Goodpasture’s Syndrome)
*flu-like illness may precede the onset
*acutely ill with oliguria, fluid overload, nephritic syndrome, and pulmonary hemorrhage if Goodpasture’s
*positive anti-GBM antibodies; can also have positive ANCA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

anti-glomerular basement membrane disease (anti-GBM) - treatment

A

*plasma exchange to remove the antibody
*immunosuppression to decrease antibody production (corticosteroids, cyclophosphamide)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

anti-glomerular basement membrane disease (anti-GBM) - prognosis

A

*kidney and patient survival correlate with the degree of kidney injury at presentation
*patients who survive the first year with intact kidney function do well, relapses are uncommon

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

immune complex-mediated RPGN

A

*any nephritic immune complex-mediated glomerulonephritis can cause crescents/RPGN
*most likely to see crescentic RPGN from nephritic processes with subendothelial deposits:
-proliferative lupus nephritis
-post-infectious glomerulonephritis
-IgA nephropathy
-MPGN

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

lupus nephritis (class III and IV) - etiology

A

*immune complex deposition causing proliferative glomerulonephritis
*genetic predisposition
*inadequate clearance of nuclei from cells undergoing apoptosis
*excess nuclear antigens + B and T cell abnormalities result in auto-antibody formation (ANA and anti-dsDNA)
*activation of toll-like receptors and dendritic cells and high interferon alpha levels
*location of antibody-antigen complexes deposit determines the injury response

17
Q

lupus nephritis - epidemiology

A

*of patients with SLE, 75% have an abnormal urinalysis
*1/3 have lupus nephritis

18
Q

lupus nephritis - clinical presentation

A

*variable: asymptomatic proteinuria/hematuria to edema to RPGN
*lupus nephritis can change classes over time

19
Q

lupus nephritis - treatments

A

*class I/II: monitor, ACEi/ARB
*class III/IV: steroids, immunosuppression
*maintenance therapy: MMF, azathioprine
*class V: immunosuppression

20
Q

mixed cryoglobulinemic vasculitis - light microscopy findings

A

*MPGN-like appearance
*lobular accentuation of glomeruli
*leukocyte infiltration
*tram track double contours
*capillary lumina with hyaline thrombi “cryo plugs”

21
Q

mixed cryoglobulinemic vasculitis - immunofluorescence findings

A

*IgM, IgG, C3, and C1q deposits (IgM prominent)

22
Q

mixed cryoglobulinemic vasculitis - electron microscopy findings

A

*subendothelial deposits with an organized structure (crystalline)

23
Q

mixed cryoglobulinemic vasculitis - etiology

A

*cryoglobulins are immunoglobulins that precipitate at temperatures lower than 37 C (lower than body temp)
*mixed cryos consist of polyclonal IgG and IgM that targets the IgG
*can cause immune complex formation and MPGN
*often result from chronic viral infections such as HEPATITIS C or from SLE

24
Q

mixed cryoglobulinemic vasculitis - clinical presentation

A

*can cause multisystem disease (arthralgias, neuropathy, erythematous macules to papules)
*renal presentation can range from isolated hematuria and/or proteinuria to nephrotic or nephritis syndrome to RPGN

25
Q

mixed cryoglobulinemic vasculitis - treatment

A

*treat underlying disorder (hep C, etc)
*in RPGN: plasma exchange, corticosteroids, immunosuppression

26
Q

Pauci immune glomerulonephritis - light microscopy findings

A

*breaks of the GBM due to fibrinoid necrosis
*crescents

27
Q

Pauci immune glomerulonephritis - immunofluorescence findings

A

*NEGATIVE (pauci-immune means no immune complexes)

note - this means that GPA & EGPA are negative on IF

28
Q

Pauci immune glomerulonephritis - electron microscopy findings

A

*no deposits

29
Q

Pauci immune glomerulonephritis - etiology

A

*necrotizing vasculitis within glomerular capillaries
*anti-neutrophil cytoplasmic antibodies (ANCA) thought to play a role:
1. c-ANCA (anti-PR3) in GPA
2. p-ANCA (anti-MPO) in MPA and EGPA
*activating of neutrophils/monocytes via binding of ANCA to target antigens on the surface of neutrophils/monocytes

30
Q

Pauci immune glomerulonephritis - clinical presentations

A

*variable: systemic sx of weight loss, decreased appetite, polymyalgia, hematuria, proteinuria; often presents as RPGN
1. GPA: upper respiratory involvement (RHINOSINUSITIS, hemoptysis) (recall: GPA is associated with c-ANCA / anti-PR3)
2. EGPA: ASTHMA (recall: EGPA is associated with p-ANCA / anti-MPO)

31
Q

Pauci immune glomerulonephritis - treatment

A

*GPA: plasma exchange, immunosuppression
*MPA: immunosuppression

32
Q

polyarteritis nodosa (PAN) - overview

A

*systemic necrotizing vasculitis of small to MEDIUM SIZED ARTERIES
*transmural inflammation with fibrinoid necrosis of arterial wall → patchy aneurysmal dilation
*causes kidney dysfunction through narrowing of inflamed arteries and ischemia
*many have HEPATITIS B
*low complements (serum C3, C4)
*HTN, azotemia, microaneurysm rupture with renal infarction
*signs of systemic inflammation: abdominal pain, fever, myalgias, rash, peripheral neuropathy

33
Q

cyclophosphamide - MOA

A

*ALKYLATING AGENT that prevents cell division by cross-linking DNA strands → decreased DNA synthesis
*cell cycle phase nonspecific agent
*potent immunosuppresive drug
*prodrug; must be metabolized by the liver

34
Q

cyclophosphamide - pharmacodynamics

A

*well absorbed orally
*metabolized by the liver, excreted by the kidney

35
Q

cyclophosphamide - ADEs

A

*alopecia
*gonadal suppression / infertility
*HEMORRHAGIC CYSTITIS (give MESNA)
*leukopenia

36
Q

rituximab - MOA

A

*monoclonal antibody directed against CD20 antigen on B-lymphocytes
*regulates cell cycle initiation
*binds to antigen on the cell surface, activating complement-dependent B cell cytotoxicity
*goal = inhibit antibody production

37
Q

rituximab - pharmacodynamics

A

*detectable in serum 3-6 months after completion of treatment
*B-cell recovery begins about 6 mo following completion of tx

38
Q

rituximab - ADEs

A

*allergic reactions
*CYTOPENIAS
*neuropathy, weakness, muscle spasms, arthralgia
*REACTIVATION OF HEP B; PML; TUBERCULOSIS
*reactivation of other viruses (shingles)